Drugs / Normobaric Hyperoxia
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04681651 | Apr 2021 → May 2023 | ischemic stroke | Capital Medical University | Completed | No outcome recorded |
| Phase 2 | NCT02407028 | Jun 2018 → Oct 2028 expected | traumatic brain injury | Gaylan Rockswold | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Normobaric Hyperoxia | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02407028 ↗ |
| Modality | Other / unclassified | “Normobaric Hyperoxia (NBH meaning 100% O2 at 1.0 ATA)” NCT02407028 ↗ |
| Route | Inhaled | “Normobaric hyperoxia treatment involved inhaling 100% oxygen at a flow rate of 10 L/min through a non-rebreather mask for 4 h” PMID 39922675 ↗ Feb 2025 |